“We and others have demonstrated that leflunomide , a food and drug administration approved drug to treat humans with rheumatoid arthritis, increases the expression of the anti-oxidant enzymes , NAD(P)H quinone dehydrogenase 1 (NQO1), catalase, and superoxide dismutase (SOD).”